Price data is not available
CytoMed Therapeutics Ltd (GDTC) Stock Price, Quote, News & History
GDTCNASDAQ
CytoMed Therapeutics teams with SunAct for a Phase 1/2 trial on gamma delta T cells in cancer therapy, advancing affordable immunotherapy solutions.
You can purchase shares of CytoMed Therapeutics (NASDAQ:GDTC) through any online brokerage.
Other companies in CytoMed Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
CytoMed Therapeutics has a consensus price target of $5.00.
The stock price for CytoMed Therapeutics (NASDAQ: GDTC) is $0.8413 last updated October 23, 2026 at 6:39 PM EDT.
There are no upcoming dividends for CytoMed Therapeutics.
CytoMed Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for CytoMed Therapeutics.
CytoMed Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of...
